CN110665074A - Heparin coating composition and preparation method thereof - Google Patents
Heparin coating composition and preparation method thereof Download PDFInfo
- Publication number
- CN110665074A CN110665074A CN201911022653.9A CN201911022653A CN110665074A CN 110665074 A CN110665074 A CN 110665074A CN 201911022653 A CN201911022653 A CN 201911022653A CN 110665074 A CN110665074 A CN 110665074A
- Authority
- CN
- China
- Prior art keywords
- heparin
- emulsion
- polyurethane emulsion
- water
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/068—Use of macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/42—Anti-thrombotic agents, anticoagulants, anti-platelet agents
Abstract
The invention relates to the field of biological medicine preparations, in particular to a heparin coating composition and a preparation method thereof. The invention comprises 2-8% of aqueous polyurethane emulsion, 0.3-5% of polyvinylidene fluoride emulsion, 1-6% of polyacrylate emulsion and the balance of heparin aqueous solution. The service life of the invention is long.
Description
Technical Field
The invention relates to the field of biological medicine preparations, in particular to a heparin coating composition and a preparation method thereof.
Background
Heparin, first discovered from the liver, is known as mucopolysaccharidosis consisting of glucosamine, L-iduroniside, N-acetylglucosamine and D-glucuronic acid, which has an average molecular weight of 15KD and is strongly acidic. It is also present in tissues such as lung, vessel wall, intestinal mucosa, etc., and is a natural anticoagulant substance in animal body. Naturally occurring in mast cells, are now predominantly extracted from the mucosa of the bovine lung or porcine small intestine. As an anticoagulant, it is a polymer formed by alternatively connecting two kinds of polysaccharides, and has anticoagulant effect both inside and outside the body. The preparation is mainly used for thromboembolic diseases, myocardial infarction, cardiovascular operations, cardiac catheter examination, extracorporeal circulation, hemodialysis and the like in clinic. With the progress of pharmacology and clinical medicine, the application of heparin is continuously expanding.
Particularly in the field of hemodialysis, in the prior art, in order to avoid the complication of in vitro coagulation of a patient during hemodialysis, heparin is required to be prefilled during the process of prefilling a hemodialysis tube and then connected to a human body for hemodialysis circulation in a state of maintaining heparin filling, which is troublesome, and heparin is wasted greatly, causing great invariance to medical staff and bringing heavy economic burden to the patient.
In order to solve the problem, research of scientific researchers develops a heparin coating which can be coated on a hemodialysis pipeline, and the principle is that a certain amount of heparin is fixed through a fixing agent to simulate the vascular wall tissue of a human body, and adsorbed heparin is continuously released into blood when the blood passes through the inside of a tube, so that the anticoagulation effect is achieved in the hemodialysis process. The adsorption capacity of the adhesive of the existing heparin coating is small, the volatilization is fast, the effective period of the existing hemodialysis tube with the heparin coating is too short, the effective period is usually about half a year, and the effective period of the ordinary hemodialysis tube is usually about three years, so that the hemodialysis tube product with the heparin coating is difficult to popularize and use.
Disclosure of Invention
The invention aims to: provides a heparin coating composition, the heparin coating of which is not easy to volatilize and has long service life.
The invention is realized by the following technical scheme: a heparin coating composition characterized by: comprises 2 to 8 percent of aqueous polyurethane emulsion, 0.3 to 5 percent of polyvinylidene fluoride emulsion, 1 to 6 percent of polyacrylate emulsion and the balance of heparin aqueous solution.
For better implementation of the scheme, the following optimization scheme is also provided:
further, the heparin content in the heparin aqueous solution is 200-1000U/kg.
Further, the weight average molecular weight of the heparin in the heparin aqueous solution is 30000-50000 dalton.
Further, the water-based polyurethane emulsion is water-based non-toxic polyurethane emulsion or water-based non-toxic polyurethane emulsion containing quaternary ammonium salt.
Another object of the present invention is to: provides a preparation method of a heparin coating, and the prepared heparin coating has large heparin adsorption capacity per unit volume and is not easy to volatilize.
The second invention purpose of the invention is realized by the following scheme: a preparation method of a heparin coating is characterized by comprising the following steps: the method comprises the following steps:
the method comprises the following steps: mechanically stirring 2-8% of aqueous polyurethane emulsion and 0.3-5% of polyvinylidene fluoride emulsion to obtain a first mixed solution, wherein the stirring speed is 200-300 rmp;
step two: mechanically stirring 1-6% of polyacrylate emulsion and heparin aqueous solution to obtain a second mixed solution, wherein the stirring speed is 50-100 rmp;
step three: and (3) maintaining the temperature in the mixing container at 24.5-25.5 ℃ by using a water bath heating mode, slowly pouring the first mixed solution and the second mixed solution into the mixing container at the same time, and standing the mixing container for 3-5 hours to obtain the required heparin coating.
For better implementation of the scheme, the following optimization scheme is also provided:
further, the heparin content in the heparin aqueous solution is 200-1000U/kg.
Further, the weight average molecular weight of the heparin in the heparin aqueous solution is 30000-50000 dalton.
Further, the water-based polyurethane emulsion is water-based non-toxic polyurethane emulsion or water-based non-toxic polyurethane emulsion containing quaternary ammonium salt.
Compared with the prior art, the invention has the beneficial effects that: the composition can
Detailed Description
Example 1:
the composition in the embodiment comprises 2% of aqueous polyurethane emulsion, 0.3% of polyvinylidene fluoride emulsion, 6% of polyacrylate emulsion and the balance of heparin aqueous solution.
The content of heparin in the heparin aqueous solution is 1000U/kg, and the weight-average molecular weight of the heparin in the heparin aqueous solution is 50000 daltons. The water-based polyurethane emulsion is water-based non-toxic polyurethane emulsion.
The preparation method of the composition of the embodiment comprises the following steps:
the method comprises the following steps: mechanically stirring 2% of aqueous polyurethane emulsion and 0.3% of polyvinylidene fluoride emulsion to obtain a first mixed solution, wherein the stirring speed is 200 rmp;
step two: mechanically stirring 6% of polyacrylate emulsion and heparin aqueous solution to obtain a second mixed solution, wherein the stirring speed is 50 rmp;
step three: and (3) maintaining the temperature in the mixing container at 24.5-25.5 ℃ by using a water bath heating mode, slowly pouring the first mixed solution and the second mixed solution into the mixing container at the same time, and standing the mixing container for 5 hours to obtain the required heparin coating.
Compared with the prior art, the scheme of the embodiment has the advantages that the validity period can be as long as two years and half years through laboratory inspection, and the validity period is greatly prolonged compared with the existing half-year validity period.
Example 2:
the composition in the embodiment comprises 8% of aqueous polyurethane emulsion, 5% of polyvinylidene fluoride emulsion, 1% of polyacrylate emulsion and the balance of heparin aqueous solution.
The heparin content in the heparin aqueous solution is 200U/kg, and the weight average molecular weight of the heparin in the heparin aqueous solution is 30000 daltons. The water-based polyurethane emulsion is water-based non-toxic polyurethane emulsion containing quaternary ammonium salt.
The preparation method of the composition of the embodiment comprises the following steps:
the method comprises the following steps: mechanically stirring 8% of aqueous polyurethane emulsion and 5% of polyvinylidene fluoride emulsion to obtain a first mixed solution, wherein the stirring speed is 300 rmp;
step two: mechanically stirring 1% of polyacrylate emulsion and heparin aqueous solution to obtain a second mixed solution, wherein the stirring speed is 100 rmp;
step three: and (3) maintaining the temperature in the mixing container at 24.5-25.5 ℃ by using a water bath heating mode, slowly pouring the first mixed solution and the second mixed solution into the mixing container at the same time, and standing the mixing container for 3 hours to obtain the required heparin coating.
Compared with the previous embodiment, the effective period of the embodiment is longer and can reach three years, the base liquid has stronger adhesive force, the required heparin amount is lower, the average molecular weight of the heparin is lower, the adaptability to the environment is better, and the using effect can be kept for a long time in the environment within 30 ℃.
While the invention has been illustrated and described with respect to specific embodiments and alternatives thereof, it will be understood that various changes and modifications can be made without departing from the spirit and scope of the invention. It is understood, therefore, that the invention is not to be in any way limited except by the appended claims and their equivalents.
Claims (8)
1. A heparin coating composition characterized by: comprises 2 to 8 percent of aqueous polyurethane emulsion, 0.3 to 5 percent of polyvinylidene fluoride emulsion, 1 to 6 percent of polyacrylate emulsion and the balance of heparin aqueous solution.
2. Heparin coating composition according to claim 1, characterized in that: the heparin content in the heparin aqueous solution is 200-1000U/kg.
3. Heparin coating composition according to claim 1, characterized in that: the weight average molecular weight of the heparin in the heparin aqueous solution is 30000-50000 dalton.
4. Heparin coating composition according to claim 1, characterized in that: the water-based polyurethane emulsion is water-based non-toxic polyurethane emulsion or water-based non-toxic polyurethane emulsion containing quaternary ammonium salt.
5. The method for preparing heparin coating according to claims 1-4, wherein: the method comprises the following steps:
the method comprises the following steps: mechanically stirring 2-8% of aqueous polyurethane emulsion and 0.3-5% of polyvinylidene fluoride emulsion to obtain a first mixed solution, wherein the stirring speed is 200-300 rmp;
step two: mechanically stirring 1-6% of polyacrylate emulsion and heparin aqueous solution to obtain a second mixed solution, wherein the stirring speed is 50-100 rmp;
step three: and (3) maintaining the temperature in the mixing container at 24.5-25.5 ℃ by using a water bath heating mode, slowly pouring the first mixed solution and the second mixed solution into the mixing container at the same time, and standing the mixing container for 3-5 hours to obtain the required heparin coating.
6. The method for preparing heparin coating according to claim 5, wherein the method comprises the following steps: the heparin content in the heparin aqueous solution is 200-1000U/kg.
7. The method for preparing heparin coating according to claim 5, wherein the method comprises the following steps: the weight average molecular weight of the heparin in the heparin aqueous solution is 30000-50000 dalton.
8. The method for preparing heparin coating according to claim 5, wherein the method comprises the following steps: the water-based polyurethane emulsion is water-based non-toxic polyurethane emulsion or water-based non-toxic polyurethane emulsion containing quaternary ammonium salt.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911022653.9A CN110665074A (en) | 2019-10-25 | 2019-10-25 | Heparin coating composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911022653.9A CN110665074A (en) | 2019-10-25 | 2019-10-25 | Heparin coating composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110665074A true CN110665074A (en) | 2020-01-10 |
Family
ID=69084392
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911022653.9A Pending CN110665074A (en) | 2019-10-25 | 2019-10-25 | Heparin coating composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110665074A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040199242A1 (en) * | 2001-12-27 | 2004-10-07 | James Hong | Hybrid intravascular stent |
| US20080188924A1 (en) * | 2002-04-01 | 2008-08-07 | Advanced Cardiovascular Systems, Inc. | Hybrid stent and method of making |
| CN103709919A (en) * | 2013-12-19 | 2014-04-09 | 四川大学 | Heparinized polyurethane coating liquid and preparation method thereof |
| CN106581785A (en) * | 2014-11-04 | 2017-04-26 | 华瑞（福建）生物科技有限公司 | Intravascular stent and preparation method thereof |
| CN110144150A (en) * | 2019-05-15 | 2019-08-20 | 杨茂本 | Antibacterial barrier coat compositions and preparation method thereof for medical inspection platform |
-
2019
- 2019-10-25 CN CN201911022653.9A patent/CN110665074A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040199242A1 (en) * | 2001-12-27 | 2004-10-07 | James Hong | Hybrid intravascular stent |
| US20080188924A1 (en) * | 2002-04-01 | 2008-08-07 | Advanced Cardiovascular Systems, Inc. | Hybrid stent and method of making |
| CN103709919A (en) * | 2013-12-19 | 2014-04-09 | 四川大学 | Heparinized polyurethane coating liquid and preparation method thereof |
| CN106581785A (en) * | 2014-11-04 | 2017-04-26 | 华瑞（福建）生物科技有限公司 | Intravascular stent and preparation method thereof |
| CN110144150A (en) * | 2019-05-15 | 2019-08-20 | 杨茂本 | Antibacterial barrier coat compositions and preparation method thereof for medical inspection platform |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103333349A (en) | Hyaluronic acid-collagen composite hydrogel for injection and preparation method thereof | |
| WO2017032276A1 (en) | Bovine intestinal mucosa enoxaparin sodium, preparation method therefor, and application thereof | |
| CN107625991B (en) | Preparation method of mussel-imitated functionalized fracture adhesive | |
| CN115054723B (en) | Flexible adhesive | |
| CN103690959A (en) | Injectable hollow hydroxyapatite microsphere/chitosan composite drug carrier material and preparation method thereof | |
| CN108794771A (en) | Dual network cross-linked cellulose/fibroin albumen high intensity hydrogel and its preparation and application | |
| CN116392633A (en) | Injectable heart failure treatment hydrogel based on recombinant humanized collagen and preparation method thereof | |
| CA2362051A1 (en) | Methods and compositions for use in perfusion applications | |
| CN108926737B (en) | Medical sealing system, preparation method and application thereof | |
| CN108704164A (en) | A kind of injection cell auxiliary autologous fat transplantation object and preparation method thereof | |
| CN110624135B (en) | Preparation method of silk fibroin scaffold material capable of realizing long-acting drug sustained release | |
| CN105536064B (en) | A kind of compound soft tissue repair hydrogel and its preparation method and application | |
| CN111330072A (en) | Preparation method and application of bionic porous MSCs microspheres | |
| CN110665074A (en) | Heparin coating composition and preparation method thereof | |
| CA2595353C (en) | Platelet additive solution | |
| CN106110376B (en) | Novel polysaccharide cellulose medical adhesive with high mechanical strength and capable of promoting wound healing and preparation method thereof | |
| CN113842398A (en) | Umbilical cord mesenchymal stem cell external gel for promoting trauma healing, administration method and application | |
| CN113577387A (en) | Preparation method and application of temperature-sensitive hydrogel compounding PRP and collagen | |
| CN109503863A (en) | A kind of injection aquagel and its preparation method and application | |
| CN107980767B (en) | A kind of preservation liquid of the EPC of long-term preservation overexpression ANG-1 | |
| CN102138553A (en) | Stem cell preservation liquid for clinic use | |
| CN102429858B (en) | Preparation method and application of sustained-release BIO/IGF (6-bromoindirubin-3'-oxime/insulin-like growth factor) composite hydrogel | |
| CN106377290A (en) | Drug-loaded titanium nail and preparation method thereof | |
| CN106562953A (en) | Application of hydroxysafflor yellow A in preparing medicine for treating diabetic foot ulceration, medicine and medicine preparation method | |
| CN112826984A (en) | Heart acellular matrix composite temperature-sensitive gel and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200110 |
|
| RJ01 | Rejection of invention patent application after publication |